Pharmacologically distinct phenotypes of α1B-adrenoceptors: Variation in binding and functional affinities for antagonists

British Journal of Pharmacology

Volumn 171, Issue 21, 2014, Pages 4890-4901

  Yoshiki, Hatsumi ^a   Uwada, Junsuke ^a,b   Md Anisuzzaman, Abu Syed ^a   Umada, Hidenori ^a   Hayashi, Ryoji ^c   Kainoh, Mie ^c   Masuoka, Takayoshi ^d   Nishio, Matomo ^d   Muramatsu, Ikunobu ^a,b,d,e  

^a Division of Hematology   (Japan)

^b UNIVERSITY OF FUKUI   (Japan)

^c TORAY INDUSTRIES INC   (Japan)

^d KANAZAWA MEDICAL UNIVERSITY   (Japan)

^e Kimura Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 [4 (1H INDOL 3 YL)PIPERIDIN 1 YL] N,N DIMETHYLPROPAN 1 AMINE DIHYDROCHLORIDE; 4 (4 AMINO 6,7 DIMETHOXY 2 QUINAZOLINYL)2 [[(1,1 DIMETHYLETHYL)AMINO]CARBONYL] 1 PIPERAZINECARBOXYLIC ACID,PHENYLMETHYL ESTER HYDRATE; 5 METHYLURAPIDIL; ADRENALIN; ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1B ADRENERGIC RECEPTOR; DEOXYCORTICOSTERONE; DESIPRAMINE; L 765314; NORADRENALIN; PHENTOLAMINE; PHENYLEPHRINE; PRAZOSIN; PROBENECID; PROPRANOLOL; SILODOSIN; TAMSULOSIN; UNCLASSIFIED DRUG; 3-(4-(1H-INDOL-3-YL)PIPERIDIN-1-YL)-N,N-DIMETHYLPROPAN-1-AMINE; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; INDOLE DERIVATIVE; PIPERIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; CALCIUM CELL LEVEL; CAROTID ARTERY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; LIVER CELL; LIVER HOMOGENATE; MALE; NONHUMAN; PHENOTYPE; RAT; ANALOGS AND DERIVATIVES; ANIMAL; CELL CULTURE; CHO CELL LINE; CRICETULUS; DRUG EFFECTS; IN VITRO STUDY; LIVER; METABOLISM; PHYSIOLOGY; WISTAR RAT;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ANIMALS; CAROTID ARTERIES; CELLS, CULTURED; CHO CELLS; CRICETULUS; HEPATOCYTES; IN VITRO TECHNIQUES; INDOLES; LIVER; MALE; PHENOTYPE; PIPERIDINES; PRAZOSIN; RATS, WISTAR; RECEPTORS, ADRENERGIC, ALPHA-1;

EID: 84918822206     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12813     Document Type: Article

References (43)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol. 170: 1459-1581.
2. Anisuzzaman ASM, Nishimune A, Yoshiki H, Uwada J, Muramatsu I (2011). Influence of tissue integrity on pharmacological phenotypes of muscarinic acetylcholine receptors in the rat cerebral cortex. J Pharmacol Exp Ther 339: 186-193.
3. Anisuzzaman ASM, Uwada J, Masuoka T, Yoshiki H, Nishio M, Ikegaya Y et al. (2013). Novel contribution of cell surface and intracellular M1-muscarinic acetylcholine receptors to synaptic plasticity in hippocampus. J Neurochem 118: 958-967.
4. Arch JRS (2002). ?3-Adrenoceptor agonists: potential. pitfalls and progress. Eur J Pharmacol 440: 99-107.
5. Arunlakshana O, Sc hild HO (1959). Some quantitative uses of drug antagonists. Br J Pharmacol Chemother 14: 48-58.
6. Baker JG, Hill SJ (2007). Multiple GPCR conformations and signaling pathways: implications for antagonist affinity estimates. Trends Pharmacol Sci 28: 374-381.
7. Berry MN, Halls HJ, Grivell MB (1992). Techniques for pharmacological and toxicological studies with isolated hepatocyte suspensions. Life Sci 51: 1-16.
8. Burt RP, Chapple CR, Marchall I (1995). Evidence for a functional ?1A-(?1C-) adrenoceptor mediating contraction of the rat epididymal vas deferens and an ?1B-Adrenoceptor mediating contraction of the rat spl een. Br J Pharmacol 115: 467-475.
9. Cavalli A, Lattion AL, Hummler E, Nenniger M, Pedrazzini T, Aubert JF et al. (1997). Decreased blood pressure response in mice deficient of the alpha1b-Adre nergic receptor. Proc Natl Acad Sci USA 94: 11589-11594.
10. Cotecchia S (2010). The ?1-Adrenergic receptors: diversity of signaling networks and regulation. J Rec Signal Transduc 30: 410-419.
11. Eltze M (1996). In functional experiments, risperidone is selective, not for the B, but for the A subtype of ?1-Adrenoceptors. Eur J Pharmacol 295: 69-73.
12. Ford AP, Arredondo NF, Blue DR Jr., Bonhous DW, Jaspar J, Kava MS et al. (1996). RS-17053 (N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-Alpha, alpha-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective alpha 1A-Adrenoceptor antagonist, displays low affinity for functiona l alpha 1-Adrenoceptors in human prostate: implications for adrenoceptor classification. Mol Pharmacol 49: 209-215.
13. Furchgott RF (1972). The classification of adrenoceptors (adrenergic receptors): an evaluation from the standpoint of receptor theory. In: Blaschko H, Muscholl E (eds). Handbuch der Experimentellen Pharmacology, Vol. 3. Springer: New York, pp. 283-335.
14. Graham RM, Perez DM, Hwa J, Piascik MT (1996). Alpha 1-Adrenergic receptor subtypes. Molecular structure, function, and signaling. Circ Res 78: 737-749.
15. Hayashi R, Ohmori E, Isogaya M, Moriwaki M, Kumagai H (2000). 3-(4-(1H-indol-3-yl)piperidin-1-yl)-N,N-dimethylpropan-1-Amine dihydrochloride (ALS-77): alpha1b-Adrenergic receptor antagonists. EP00940789A.
16. Hieble JP, Bylund DB, Clarke DE, Eikenburg DC, Langer SZ, Lefkowitz RJ et al. (1995). International Union of Pharmacology. X. Recommendation for nomenclature of alpha 1-Adrenoceptors: consensus update. Pharmacol Rev 47: 267-270.
17. Jacobs S, Cuatrecasas P (1976). Binding of [3H]guanylylimidodiphosphate to membranes: lack of correlation with adenylate cyclase activation. Biochem Biophy Res Commu 70: 885-892.
18. Kenakin T (1995). On the imp ortance of the 'antagonist assumption' to how receptors express themselves. Biochem Pharmacol 50: 17-26.
19. Kenakin T (2003). Predicting therapeutic value in the lead optimization phase of drug discovery. Nat Rev Drug Discov 2: 429-438.
20. Kenakin T, Miller LJ (2010). Seven transmembrane receptors as shape shifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev 62: 265-304.
21. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
22. Lane JR,Sexton PM,Christopoulos A 2013 Briding the gap: bitopic ligands of G-protein-coupled receptors Trends Pharmacol Sci 34 59-66.
23. Lomansney JW, Cotecchia S, Lefkowitz RJ, Caron MG ( 1991). Molecular biology of alpha-Adrenergic receptors: implications for receptor classification and for structure-function relationships. Biochem Biophys Acta 1095: 127-139.
24. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
25. Michel AD, Loury DN, Whiting RL (1989). Identification of a single alpha 1-Adrenoceptor corresponding to the alpha 1A-subtype in rat submaxillary gland. Br J Pharmacol 98: 883-889.
26. Michel MC, Kenney B, Schwinn DA (1995). Classification of alpha-1 adrenoceptor subtypes. Naunyn Schmiedebergs Arch Pharmacol 352: 1-10.
27. Michelotti GA, Price DT, Schwinn DA (2000). ?1-Adrenergic receptor regulation: basic science and clinical implications. Pharmacol Ther 88: 281-309.
28. Minneman KP (1988). ?-Adrenergic receptor subtypes, inositol phosphate, and sources of cell Ca2. Pharmacol Rev 40: 87-119.
29. Mohr K, Tr nkle C, Kostenis E, Barocell E, Amici MD, Holzgrabe U (2010). Rational design of dualsteric GPCR ligands: quests and promise. Br J Pharmacol 159: 997-1008.
30. Morishima S, Tanaka T, Yamamoto H, Suzuki F, Akino H, Yokoyama O et al. (2007). Identification of ?1L-And ?1A-Adrenoceptors in human prostate by tissue segment binding. J Urol 177: 377-381.
31. Morishima S, Suzuki F, Yoshiki H, Md Anisuzzaman AMS, Sathi ZS, Tanaka T et al. (2008). Identification of the ?1L-Adrenoceptor in rat cerebral cortex and possible relationship between ?1L-And ?1A-Adrenoceptors. Br J Pharmacol 153: 1485-1494.
32. Muramatsu I, Tanaka T, Suzuki F, Li Z, Hiraizumi-Hiraoka Y, Anisuzzaman AS et al. (2005). Quantifying receptor properties: the tissue segment binding method-A powerful tool for the pharmacome analysis of native re ceptors. J Pharmacol Sci 98: 331-339.
33. Muramatsu I, Morishima S, Suzuki F, Yoshiki H, Anisuzzaman ASM, Tanaka T et al. (2008). Identification of ?1L-Adrenoceptor in mice and its abolition by ?1A-Adrenoceptor gene knockout. Br J Pharmacol 155: 1224-1234.
34. Murata S, Taniguchi T, Muramatsu I (1999). Pharmacological analysis of the novel, selective ?1-Adrenoceptor antagonist, KMD-3213, and its suita bility as a tritiated radioligand. Br J Pharmacol 127: 19-26.
35. Nelson CP, Challiss RAJ (2007). 'Phenotypic' pharmacology: the influence of cellular environment on G protein-coupled receptor antagonist and inverse agonist pharmacology. Biochem Pharmacol 73: 737-751.
36. Nishimune A, Yoshiki H, Uwada J, Anisuzzaman AS, Umada H, Muramatsu I (2012). Phenotype pharmacology of lower urinary tract ?1-Adrenoceptors. Br J Pharmacol 165: 1226-1234.
37. Patane MA, Scott AL, Broten TP, Chang RSL, Ransom RW, DiSalvo J et al. (1998). 4-Amino-2-[4-[1-(benzyloxycarbonyl)-2(S)-[ [ (1,1-dimethylethyl)amino]carbon yl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765,314): a potent and selective ?1b-Adrenergic receptor antagonist. J Med Chem 41: 1205-1208.
38. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Bun eman OP, Davenport AP, McGrath JC, Peters JA, Southan C, Spedding M, Yu W, Harmar AJ; NC-IUPHAR. (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl. Ac ids Res. 42 (Database Issue): D1098-106.
39. Sathi ZS, Anisuzzaman ASM, Morishima S, Suzuki F, Tanaka T, Yoshiki H et al. (2008). Different affinities of native ?1B-Adrenoceptors for ketanserin between int act tissue segments and membrane preparations. Eur J Pharmacol 584: 222-228.
40. Stam WB, Van der Graaf PH, Saxena PR (1998). Functional characterisation of the pharmacological profile of the putative ?1B-Adren oceptor antagonist, (+)-cyclazosin. Eur J Pharmacol 361: 79-83.
41. Testa R, Guarneri L, Angelico P, Poggesi E, Taddei C, Sironi G et al. (1997). Pharmacological characterization of the uroselec tive alpha-1 antagonist Rec 15/2739 (SB 216469): role of the alpha-1 L adrenoceptor in tissue selectivity, part II. J Pharmacol Exp Ther 281: 1284-1293.
42. Tuong MDT, Garbarg M, Schwartz JC (1980). Pharmacological specificity of brain histamine H2-receptors differs in intact cells and cell-free preparations. Nature 287: 548-551.
43. Yoshiki H,Uwada J,Umada H,Kobayashi T,Takahashi T,Yamakawa T,et al 2013 Agonist pharmacology at recombinant ?1A-And ?1L-Adrenoceptors and in lower urinary ?1-Adrenoceptors Br J Pharmacol 170: 1242-1252.